F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.
Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.
Lighthouse
Series C in 2024
Lighthouse is a commercial platform focused on the travel and hospitality industry, previously known as OTA Insight. The company offers a hotel management platform that visualizes and leverages data to enhance business success. Its cloud-based data intelligence tools provide real-time, actionable insights that empower hoteliers and hotel management companies to make informed revenue and distribution decisions. By facilitating customer support services, Lighthouse helps maximize property occupancy rates and drive revenue growth, transforming complex market conditions into clear, actionable strategies for its clients.
Canoe
Series C in 2024
Canoe focuses on automating document management and data extraction for allocators and investors into alternatives. The company is transforming the post-investment operational, monitoring, and reporting experience for all involved. By combining industry expertise with sophisticated machine-learning and data capture technologies, it turns PDF reporting documents into actionable data and intelligence, unlocking new operational efficiencies for clients. Canoe was founded in 2013 and based in New York, New York.
Odaseva
Series C in 2024
Odaseva is a company that specializes in data management solutions for large enterprises using Salesforce. Its platform provides comprehensive data governance that focuses on data protection, privacy, and operational efficiency. Key features include backup and recovery, archiving, monitoring of governor limits, and compliance with regulatory requirements such as GDPR. Odaseva's tools enable businesses to manage their Salesforce data effectively, ensuring its confidentiality, integrity, and availability. By offering a range of integrated security products and services, Odaseva empowers organizations to take full control of their data, mitigate risks, and accelerate their digital transformation initiatives.
Canary Technologies
Series C in 2024
Canary Technologies LLC, based in San Francisco, California, specializes in developing innovative software solutions for the hospitality industry, focusing on enhancing operational efficiency and improving guest experiences. The company's platform modernizes outdated hotel management processes by offering features such as contactless check-in, digital authorizations, electronic signatures, and a customizable amenity store. These tools are designed to streamline workflows, reduce costs, increase revenue, and enhance compliance, making them invaluable to hoteliers. Trusted by numerous prestigious hotel brands worldwide, Canary Technologies aims to drive greater productivity and minimize fraud within the sector.
Ashby
Series C in 2024
Ashby is a developer of recruitment software specifically designed for high-growth companies. The company offers an enterprise-grade platform that streamlines the hiring process, making it more effective for company leaders, recruiters, and hiring managers. By providing a user-friendly solution, Ashby enables organizations of various sizes to enhance their recruitment strategies and meet their growth objectives more efficiently.
Genomics
Series C in 2024
Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.
1upHealth
Series C in 2023
1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.
ABK Biomedical
Series C in 2022
ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization.
Proximie
Series C in 2022
Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.
RightHand Robotics
Series C in 2022
RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.
Stride Health
Series C in 2021
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.
Funnel
Series C in 2021
Funnel is a marketing analytics and reporting software that aims to streamline data collection for online advertisers and e-commerce companies. Founded in 2014 by Fredrik Skantze and Per Made, the company provides a platform that integrates with over 400 marketing and advertising sources. This allows businesses to automatically collect and structure advertising performance data, facilitating better decision-making regarding advertising spend and business growth. Funnel enables users to feed data into various tools, including Business Intelligence platforms, Data Warehouses, and visualization tools like Google Data Studio and Google Analytics. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B enterprises, mobile applications, and gaming companies. Funnel operates from its headquarters in Stockholm, with an additional office in Boston.
Oviva
Series C in 2021
Oviva UK Limited is a healthcare company based in London that specializes in digitally-enabled behavior change programs focused on diet and lifestyle-related health conditions, particularly type 2 diabetes and obesity. Founded in 2015, Oviva has developed a unique platform that combines a smartphone app and learning portals to provide personalized coaching and nutritional advice. This approach allows patients to engage in behavior change without the need for in-person clinic visits, thereby improving health outcomes and reducing costs for healthcare systems by preventing complications associated with these conditions. By leveraging a network of qualified consultants, Oviva aims to support individuals in achieving better health through tailored interventions.
Carrot Fertility
Series C in 2021
Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.
MoEngage
Series C in 2021
MoEngage, Inc. is a cloud-based marketing and customer engagement platform founded in 2014 and headquartered in San Francisco, California, with additional offices in several international locations including India, Singapore, and the United Kingdom. The platform specializes in user analytics and engagement, offering tools for personalized interactions through various channels such as push notifications, in-app messaging, web, and SMS. It leverages machine learning to optimize customer engagement and improve retention and lifetime value for businesses across industries like e-commerce, telecom, travel, and finance. MoEngage's comprehensive dashboard enables clients to analyze customer behavior and manage campaigns efficiently, thereby enhancing their marketing efforts and attracting new customers. The company has also established a strategic partnership with Vidora, Inc. to further enhance its service offerings.
SonderMind
Series C in 2021
SonderMind is a digital health and telehealth company based in Denver, Colorado, that aims to enhance access to behavioral health services. Founded in 2014, it operates an online directory connecting individuals with independent professionals offering mental health, massage, acupuncture, and nutrition services. The platform simplifies the process of finding well-matched therapists, allowing consumers to quickly access trusted care while enabling therapists to concentrate on patient treatment without the burden of administrative tasks. SonderMind combines various software tools and an integrated provider network to deliver high-quality behavioral healthcare, serving consumers, employers, and health systems effectively. The company's mission is to make behavioral health services more accessible and utilized.
Orient Speech Therapy
Series C in 2021
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.
Pulmocide
Series C in 2021
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
CareStack
Series C in 2021
CareStack is a single all-in-one platform on the cloud that combines dental practice management, patient engagement, practice marketing, and data analytics. CareStack is currently used by large and growing practices as an all-in-one solution to increase productivity, minimize costs, and improve patient dental care. CareStack's mission is to help dentists to have a better practice and a better life. Through their technology-led offerings, CareStack will elevate dental offices to a higher degree of financial success.
SnapDocs
Series C in 2020
Snapdocs, Inc. is a real estate technology firm based in San Francisco that specializes in creating a digital platform for mortgage closings. Founded in 2013, Snapdocs connects lenders, title companies, and notary signing agents to enhance the efficiency and accuracy of the closing process. The platform automates interactions and workflows, allowing for streamlined operations and improved customer experiences. It offers features that enable lenders to adopt digital closings, providing flexibility in closing types, while also allowing title and escrow clients to automate their workflows. Notary signing agents can showcase their qualifications, and home buyers gain early access to their closing packages, fostering a smoother transaction. By leveraging advanced automation and AI technology, Snapdocs aims to simplify the complexities of mortgage closings, ultimately saving time and reducing costs for all participants involved.
Checkmate Pharmaceuticals
Series C in 2020
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.
PatientPing
Series C in 2020
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.
Devoted
Series C in 2020
Devoted Health is a healthcare company focused on enhancing the health and well-being of older Americans by treating each individual with care and compassion. The company offers an integrated healthcare solution that includes Medicare Advantage plans, access to local providers, and the option for virtual and in-home care through Devoted Medical. Their approach includes personalized medical plans and dedicated guides who work closely with physicians to streamline care and minimize unnecessary procedures. By leveraging advanced technology and a robust network of healthcare professionals, Devoted Health aims to provide high-quality, tailored healthcare services to its members.
Whatfix
Series C in 2020
Whatfix is a developer of a digital adoption platform that enhances user experience through personalized, real-time application guidance and support. By offering simulated application environments for training and no-code application analytics, Whatfix disrupts traditional training methods by delivering contextual and interactive support directly within applications. This approach enables organizations to improve user productivity, ensure process compliance, and streamline workflows across web, desktop, and mobile platforms. Additionally, the platform leverages generative AI to provide insights that help clients make informed decisions, ultimately driving greater adoption and efficiency in business-critical operations.
MoEngage
Series C in 2020
MoEngage, Inc. is a cloud-based marketing and customer engagement platform founded in 2014 and headquartered in San Francisco, California, with additional offices in several international locations including India, Singapore, and the United Kingdom. The platform specializes in user analytics and engagement, offering tools for personalized interactions through various channels such as push notifications, in-app messaging, web, and SMS. It leverages machine learning to optimize customer engagement and improve retention and lifetime value for businesses across industries like e-commerce, telecom, travel, and finance. MoEngage's comprehensive dashboard enables clients to analyze customer behavior and manage campaigns efficiently, thereby enhancing their marketing efforts and attracting new customers. The company has also established a strategic partnership with Vidora, Inc. to further enhance its service offerings.
WelbeHealth
Series C in 2020
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Wellframe
Series C in 2019
Wellframe Inc. is a Boston-based company that specializes in digital care management solutions aimed at enhancing the relationship between health plans and their members. Founded in 2011, Wellframe develops a mobile patient engagement platform that utilizes real-time member-generated data and artificial intelligence to create personalized care protocols. Its offerings include a member mobile application for daily health tracking, a care team dashboard for prioritizing patient needs, and two-way communication solutions. The company also provides various services such as implementation, operational change management, and analytics. Additionally, Wellframe's digital health advocate solutions encompass intake assessments, concierge programs, and integrated workflows to enhance care management. The company's strategic partnerships with health plans nationwide allow it to deliver impactful health management solutions that empower patients and improve care outcomes.
Recurly
Series C in 2019
Recurly, Inc. specializes in enterprise-class subscription management solutions that streamline and automate revenue growth for businesses across various industries, including digital media, streaming, publishing, SaaS, consumer goods, and professional services. Founded in 2009 and headquartered in San Francisco, California, with additional offices in Boulder, Colorado, and New Orleans, Louisiana, Recurly offers a comprehensive platform for managing subscription billing and optimizing payment acceptance. Its services include customizable billing pages, account management, and deep payments expertise, allowing clients to enhance their subscriber economics and reduce churn. The platform enables quick integrations and user-friendly dashboards, facilitating efficient handling of billing issues such as upgrades, downgrades, voids, and refunds. Recurly also helps clients minimize costs associated with PCI compliance, making it a valuable partner for businesses looking to improve their revenue operations and decision-making through data-driven insights.
Protenus
Series C in 2019
Protenus, Inc. is a company based in Baltimore, Maryland, that specializes in developing a compliance analytics platform for healthcare organizations in the United States. Founded in 2014, Protenus utilizes artificial intelligence to audit access to patient records, helping to identify risks such as inappropriate access and the misuse of controlled substances by hospital staff. The platform enables healthcare providers to proactively detect policy violations and anomalous behaviors, ultimately supporting safer patient outcomes while safeguarding the integrity of health data. Through its innovative solutions, Protenus aims to reduce risk and protect the reputation of healthcare organizations, affirming its commitment to both patient safety and organizational accountability.
Simon Data
Series C in 2019
Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.
Artemis Health
Series C in 2019
Artemis Health Inc. is a health data analytics company that offers a platform designed to assist self-insured employers in optimizing their benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company provides actionable insights into benefits, identifying opportunities and gaps that employers can address. The platform enables users to pinpoint issues within their benefit offerings, share findings with relevant stakeholders, and implement solutions to enhance their programs. Additionally, it tracks the effectiveness of these solutions, allowing employers to make informed, data-driven decisions aimed at minimizing healthcare expenditures while improving employee health and wellness coverage.
Checkmate Pharmaceuticals
Series C in 2018
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.
PharmEasy
Series C in 2018
PharmEasy is a health tech startup founded in 2015 by Dharmil Sheth, Mikhil Innani, and Dhaval Shah, operating as a subsidiary of Ascent Health. The company offers an online platform that streamlines the supply chain of pharmaceuticals by digitizing the process of medicine delivery. It provides services such as teleconsultation, medicine deliveries, and diagnostic test sample collections, facilitating connections between patients and local pharmacy stores and diagnostic centers. By improving accessibility and affordability, PharmEasy aims to meet extensive medical needs and enhance the overall healthcare experience for its users. The startup is backed by several prominent investors, including Caisse de Dépôt et Placement du Québec, Bessemer Venture Partners, and Temasek Holdings.
Quartet Health
Series C in 2018
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.
Threat Stack
Series C in 2017
Threat Stack is a provider of a cloud security platform that supports DevOps and SecOps teams in managing security risks within cloud, hybrid-cloud, and containerized environments. The platform offers continuous security monitoring and risk assessment, enabling organizations to detect insider threats, external attacks, and compliance gaps in real-time. By delivering full-stack security observability throughout the application development lifecycle, Threat Stack helps enterprises achieve regulatory compliance and safeguard against potential data loss. This comprehensive approach enhances the ability of security and operations teams to innovate and scale securely while addressing complex cloud security needs.
Promentis Pharmaceuticals
Series C in 2017
Promentis Pharmaceuticals discovers, develops, and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals was founded in 2006 and is based in Milwaukee, Wisconsin.
Snapsheet
Series C in 2016
Snapsheet is a cloud-native claims management software company that specializes in transforming the end-to-end claims process through digitization and intelligent automation. The company offers a comprehensive suite of services, including electronic intake of first notice of loss (FNOL), data investigation, technology-assisted investigation, claims assessment, and digital payment processing for settlements. By leveraging its technology-enabled appraisal services, Snapsheet enhances customer experience and increases organizational agility for its clients. The company is known for deploying one of the fastest digital auto insurance claims processes in the United States. As a trusted innovation partner, Snapsheet collaborates with over 100 clients, including major insurance carriers, third-party administrators, and disruptors in the insurtech and sharing economy sectors.
TraceLink
Series C in 2016
TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.
Hua Medicine
Series C in 2016
Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.
Kyruus
Series C in 2015
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.
Aclaris Therapeutics
Series C in 2015
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.
Iora Health
Series C in 2015
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.
Innovent Biologics
Series C in 2015
Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.
Regenxbio
Series C in 2015
REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.
Flywire
Series C in 2015
Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.
ViewRay
Series C in 2012
ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Fluidnet
Series C in 2011
Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.
NextWave Pharmaceuticals
Series C in 2011
NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology.
ViewRay
Series C in 2010
ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Tetraphase Pharmaceuticals
Series C in 2010
Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.
Ironwood Pharmaceuticals
Series C in 2002
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.